AstraZeneca's Defeat Sets Precedent For Future IRA Disputes In Pharmaceuticals Sector
Pharmaceuticals / United States / Mon 11 Mar, 2024
Key View
- Further dismissals of lawsuits targeting the Inflation Reduction Act (IRA) will continue to pose downside risks to drugmakers in the US.
- Negotiations will set a precedent for drug pricing, as drugmakers present counter offers to Centers for Medicare and Medicaid Services (CMS).
- Drugmakers and relevant stakeholders implicated in